Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity

Pediatric Transplantation

Volumn 10, Issue 6, 2006, Pages 721-729

  Tönshoff, Burkhard ^a   Höcker, Britta ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Calcineurin inhibitors; Mycophenolate mofetil; Nephrotoxicity; Sirolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS;

ALLOIMMUNITY; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY GRAFT; LIFE EXPECTANCY; LIVER; LIVER DYSFUNCTION; LIVER GRAFT; NONHUMAN;

CALCINEURIN; CHILD; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; SIROLIMUS; TACROLIMUS;

EID: 33746867060     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00577.x     Document Type: Conference Paper

References (40)

1. CHAPMAN JR, O'CONNELL PJ, NANKIVELL BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005: 16: 3015-3026.
2. The 2005 NAPRTCS Annual Report. http://www.naprtcs.org Accessed February 15, 2006.
3. NANKIVELL BJ, BORROWS RJ, FUNG CL, O'CONNELL PJT, ALLEN RD, CHAPMAN JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326-2333.
4. MYERS BD, NEWTON L. Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 1991: 2: 45-52.
5. BERTANI T, FERRAZZI P, SCHIEPPATI A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991: 40: 243-250.
6. OJO AO, HELD PJ, PORT FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931-940.
7. ABRAMOWICZ D, MANAS D, LAO M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation 2002: 74: 1725-1734.
8. DUDLEY C, POHANKA E, RIAD H, et al. Mycophenolate Mofetil Creeping Creatinine Study Group. Mycophenolate mofetil substitution for cyclosporine in renal transplant recipients with chronic progressive allograft dysfunction: The 'creeping creatinine' study. Transplantation 2005: 79: 466-475.
9. KEUNECKE C, ROTHENPIELER U, ZANKER B, et al. Mycophenolate mofetil monotherapy: An example of a safe nephrotoxicity/ atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients. Transplant Proc 2000: 32: 6-8.
10. LAND W. Mycophenolate mofetil-based immunosuppressive therapy: Induction, maintenance, and conversion protocols in renal transplantation. Transplant Proc 1999: 31: 27-32.
11. SCHNUELLE P, VAN DER HEIDE JH, TEGZESS A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002: 3: 536-543.
12. SMAK GREGOOR PJ, VAN GELDER T, VAN BESOUW NM, VAN DER MAST BJ, IJZERMANS JN, WEIMAR W. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000: 15: 143-148.
13. TAPIA E, FRANCO M, SANCHEZ-LOZADA LG, et al. Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int 2003: 63: 994-1002.
14. AFZALI B, SHAH S, CHOWDHURY P, O'SULLIVAN H, TAYLOR J, GOLDSMITH D. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005: 79: 304-309.
15. WEIR MR, WARD MT, BLAHUT SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001: 59: 1567-1573.
16. WEIR MR, BLAHUT S, DRACHENBURG C, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004: 24: 379-386.
17. ABRAMOWICZ D, DEL CARMEN RIAL M, VITKO S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005: 16: 2234-2240.
18. CIANCIO G, BURKE GW, GAYNOR JJ, et al. A randomized long-term trial of tacrolimus/sirolimus vs. tacrolimus/mycophenolate mofetil vs. cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004: 77: 252-258.
19. CIANCIO G, BURKE GW, GAYNOR JJ, et al. A randomized long-term trial of tacrolimus and sirolimus vs. tacrolimus and mycophenolate mofetil vs. cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004: 77: 244-251.
20. KUYPERS DR, EVENEPOEL P, MAES B, COOSEMANS W, PIRENNE J, VANRENTERGHEM Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003: 17: 234-241.
21. LO A, EGIDI MF, GABER LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitorfree regimens in cadaveric renal transplantation. Transplantation 2004: 77: 1228-1235.
22. PASCUAL M, CURTIS J, DELMONICO FL, et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003: 75: 1501-1505.
23. HENNE T, LATTA K, STREHLAU J, PAPE L, EHRICH JH, OFFNER G. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003: 76: 1326-1330.
24. FERRARIS JR, TAMBUTTI ML, REDAL MA, BUSTOS D, RAMIREZ JA, PRIGOSHIN N. Conversion from azathioprine [correction of azathioprina] to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation 2000: 70: 297-301.
25. BENFIELD MR. Current status of kidney transplant: Update 2003. Pediatr Clin North Am 2003: 50: 1301-1334.
26. FILLER G, GELLERMANN J, ZIMMERING M, MAI I. Effect of adding mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. Transpl Int 2000: 13: 201-206.
27. DAVID-NETO E, ARAUJO LM, LEMOS FC, et al. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy. Pediatr Transplant 2001: 5: 302-309.
28. HOECKER B, FENEBERG R, KÖPF S, et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006 (in press).
29. ARORA-GUPTA N, DAVIES P, MCKIERNAN P, KELLY DA. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant 2004: 8: 145-150.
30. BARTOSH SM, ALONSO EM, WHITINGTON PF. Renal outcomes in pediatric liver transplantation. Clin Transplant 1997: 11: 354-360.
31. MCDIARMID SV. Renal function in paediatric liver transplant patients. Kidney Int 1996: 53: 77-84.
32. EVANS HM, MCKIERNAN PJ, KELLY DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005: 15: 1575-1580.
33. MENTION K, LAHOCHE-MANUCCI A, BONNEVALLE M, et al. Renal function outcome in pediatric liver transplant recipients. Pediatr Transplant 2005: 9: 201-207.
34. FERRARIS JR, DUCA P, PRIGOSHIN N, et al. Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction: Changes in the immune responses. Pediatr Transplant 2004: 8: 454-459.
35. SCHEENSTRA R, TORRINGA ML, WAALKENS HJ, et al. Cyclosporine A withdrawal during follow-up after pediatric liver transplantation. Liver Transpl 2006: 12: 240-246.
36. BOUCEK MM, EDWARDS LB, KECK BM, et al. The Registry of the International Society for Heart and Lung Transplantation: Sixth Official Pediatric Report - 2003. J Heart Lung Transplant 2003: 22: 636-652.
37. SIGFUSSON G, FRICKER FJ, BERNSTEIN D, et al. Long-term survivors of pediatric heart transplantation: A multicenter report of sixty-eight children who have survived longer than five years. J Pediatr 1997: 130: 862-871.
38. WEBBER SA. 15 years of pediatric heart transplantation at the University of Pittsburgh: Lessons learned and future prospects. Pediatr Transplant 1997: 1: 8-21.
39. SWENSON JM, FRICKER FJ, ARMITAGE JM. Immunosuppression switch in pediatric heart transplant recipients: Cyclosporine to FK 506. J Am Coll Cardiol 1995: 25: 1183-1188.
40. BOYER O, LE BIDOIS J, DECHAUX M, GUBLER MC, NIAUDET P. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 2005: 27: 1405-1410.